The penetration of rufloxacin into sites of potential infection in the respiratory tract.
The concentrations of rufloxacin in the bronchial mucosal, pulmonary epithelial lining fluid and alveolar macrophages were determined in specimens obtained at fibreoptic bronchoscopy. A single oral dose of rufloxacin 400 mg was administered and the samples obtained in the following 72 h. The mean peak serum concentration was 3.56 mg/L, yet the agent was concentrated 1.8-fold in bronchial mucosa, 21.6-fold in alveolar macrophages and 7.7-fold in epithelial lining fluid (as measured by AUC ratios).
Wise
R
R
Department of Medical Microbiology, Dudley Road Hospital, Birmingham, UK.
Andrews
J
J
Imbimbo
B P
BP
Greaves
I
I
Honeybourne
D
D
D000890:Anti-Infective Agents / Q000097:blood / Q000493:pharmacokinetics*; D001980:Bronchi / Q000378:metabolism; D001992:Bronchoalveolar Lavage Fluid; D004848:Epithelium / Q000378:metabolism; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008168:Lung / Q000378:metabolism*; D016676:Macrophages, Alveolar / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000378:metabolism; D015363:Quinolones / Q000097:blood / Q000493:pharmacokinetics*; D012141:Respiratory Tract Infections / Q000378:metabolism*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C060328:rufloxacin